Monopar Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:MNPR

Comments

Monopar Therapeutics Inc Earnings Estimates

MNPRNASDAQ

Trade with Public

$53.47

-1.34-2.44%

At close: Feb 27, 4:00 PM EST

$53.47

-1.34-2.44%

Pre-Market: 7:14 AM EST

Overview NewsEarningsAnalyst Ratings Insider Trades Short Interest Stock Report

Monopar Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:MNPR

Monopar Therapeutics (MNPR) is scheduled to report Q4 earnings on March 30, 2026. Analysts estimate EPS of $-0.54 and quarterly revenue of N/A.

In the most recent quarter (Q3), Monopar Therapeutics reported EPS of $-0.48, missing estimates of $-0.42 by 0.14%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Over the last 4 quarters, Monopar Therapeutics has averaged an EPS surprise of 1.26% and a revenue surprise of 0.00%.

Earnings Date

Mar 30

EPS Estimate

$-0.540

Quarterly Revenue Estimate

–

Annual Revenue
(as of Sep 30)

–

Monopar Therapeutics Earnings History

Analyze the earnings history of Monopar Therapeutics using advanced sorting and filters.

Monopar Therapeutics (MNPR) Earnings Per Share

The chart below shows Monopar Therapeutics's reported EPS compared to analyst estimates over recent quarters.

Monopar Therapeutics (MNPR) Revenue

The chart below shows Monopar Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Monopar Therapeutics (NASDAQ:MNPR) reporting earnings?

Monopar Therapeutics (MNPR) is scheduled to report earnings on May 12, 2026. The last reported earnings were for reported on November 13, 2025 for Q3.

What were the latest earnings per share (EPS) for Monopar Therapeutics (NASDAQ:MNPR)?

The Actual EPS was $-0.48, which missed the estimate of $-0.42.

What were Monopar Therapeutics’s (NASDAQ:MNPR) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

Armata Pharmaceuticals Inc

AMEX:ARMP

$10.84

-5.35%

DiaMedica Therapeutics Inc

NASDAQ:DMAC

$7.90

1.52%

Bicycle Therapeutics PLC

Greenwich LifeSciences Inc

NASDAQ:GLSI

$26.75

-2.39%

Crescent Biopharma Inc

NASDAQ:CBIO

$11.42

1.93%

Monopar Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:MNPR

Monopar Therapeutics (MNPR) is scheduled to report Q4 earnings on March 30, 2026. Analysts estimate EPS of $-0.54 and quarterly revenue of N/A.

In the most recent quarter (Q3), Monopar Therapeutics reported EPS of $-0.48, missing estimates of $-0.42 by 0.14%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Over the last 4 quarters, Monopar Therapeutics has averaged an EPS surprise of 1.26% and a revenue surprise of 0.00%.

Earnings Date

Mar 30

EPS Estimate

$-0.540

Quarterly Revenue Estimate

–

Annual Revenue
(as of Sep 30)

–